ACM
CORT icon

Aster Capital Management’s Corcept Therapeutics CORT Stock Holding History

Aster Capital Management’s Portfolio CORT Stock Details CORT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		– Sell
-33
Closed -$3.77K – 924
2026
Q1 		$3.77K Sell
33
-144
-81% -$5.38K ﹤0.01% 704
2025
Q4 		$6.16K Buy
+177
New +$13.9K ﹤0.01% 836
2025
Q3 		– Sell
-3,128
Closed -$230K – 1033
2025
Q2 		$230K Buy
3,128
+1,334
+74% +$96.7K 0.05% 349
2025
Q1 		$109K Buy
1,794
+1,750
+3,977% +$107K 0.02% 635
2024
Q4 		$2.22K Buy
+44
New +$2.31K ﹤0.01% 961

Other funds holding CORT

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
ISL
Ingalls & Snyder LLC New York $3.66B AUM 57.76% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
PA
Parallel Advisors San Francisco, California $6.56B AUM 32.24% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
AQR Capital Management
AQR Capital Management Greenwich, Connecticut $287B AUM 42.33% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Aster Capital Management's CORT Position: Q2 2026 in Review

Aster Capital Management sold out of Corcept Therapeutics (CORT) in Q2 2026, closing a stake of 33 shares — an estimated $3.77K sold.

Aster Capital Management first reported a position in CORT in Q4 2024 and held it in 5 quarters. The position peaked at $230K in Q2 2025. 423 funds tracked by Wall St. Rank hold CORT as of Q2 2026.

  • Aster Capital Management reported no remaining Corcept Therapeutics position as of Q2 2026 after selling out during the quarter.
  • Aster Capital Management sold 33 Corcept Therapeutics shares in Q2 2026, an estimated $3.77K.
  • Aster Capital Management first reported a position in Corcept Therapeutics in Q4 2024 and held it in 5 quarters.
  • Aster Capital Management's Corcept Therapeutics position peaked at $230K in Q2 2025.
  • 423 funds tracked by Wall St. Rank held Corcept Therapeutics as of Q2 2026.

Based on Aster Capital Management's 13F filing for Q2 2026, filed 13 Aug 2026.